SG11202012524YA - Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same - Google Patents
Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of sameInfo
- Publication number
- SG11202012524YA SG11202012524YA SG11202012524YA SG11202012524YA SG11202012524YA SG 11202012524Y A SG11202012524Y A SG 11202012524YA SG 11202012524Y A SG11202012524Y A SG 11202012524YA SG 11202012524Y A SG11202012524Y A SG 11202012524YA SG 11202012524Y A SG11202012524Y A SG 11202012524YA
- Authority
- SG
- Singapore
- Prior art keywords
- disubstituted
- novel
- same
- pharmaceutical use
- pyridazine derivatives
- Prior art date
Links
- -1 3, 5-disubstituted pyridine Chemical class 0.000 title 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018141254 | 2018-07-27 | ||
PCT/JP2019/029366 WO2020022470A1 (ja) | 2018-07-27 | 2019-07-26 | 新規3,5-二置換ピリジン及び3,5-二置換ピリダジン誘導体及びその医薬用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012524YA true SG11202012524YA (en) | 2021-01-28 |
Family
ID=69181769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012524YA SG11202012524YA (en) | 2018-07-27 | 2019-07-26 | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same |
Country Status (22)
Country | Link |
---|---|
US (1) | US11958812B2 (zh) |
EP (2) | EP4219452A1 (zh) |
JP (2) | JP7440413B2 (zh) |
KR (1) | KR20210038896A (zh) |
CN (1) | CN112469699B (zh) |
AR (1) | AR115852A1 (zh) |
AU (1) | AU2019311595B2 (zh) |
BR (1) | BR112020027051A2 (zh) |
CA (1) | CA3103648A1 (zh) |
DK (1) | DK3831812T3 (zh) |
ES (1) | ES2952939T3 (zh) |
FI (1) | FI3831812T3 (zh) |
HU (1) | HUE062356T2 (zh) |
IL (1) | IL279702B2 (zh) |
MX (1) | MX2021001034A (zh) |
PH (1) | PH12021550061A1 (zh) |
PL (1) | PL3831812T3 (zh) |
PT (1) | PT3831812T (zh) |
SG (1) | SG11202012524YA (zh) |
TW (1) | TWI833781B (zh) |
WO (1) | WO2020022470A1 (zh) |
ZA (1) | ZA202100352B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11485727B2 (en) * | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
US11465982B2 (en) * | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
JP7442130B2 (ja) | 2020-03-13 | 2024-03-04 | 国立大学法人 東京大学 | 緑内障の病型を検査する方法及び検査試薬 |
WO2024026290A1 (en) | 2022-07-25 | 2024-02-01 | Cayman Chemical Company Incorporated | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS |
WO2024098210A1 (zh) * | 2022-11-07 | 2024-05-16 | 深圳博瑞医药科技有限公司 | 一种芳基羧酸类化合物及其制备Mrgpr X4抑制剂的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
NZ603575A (en) * | 2010-07-06 | 2014-03-28 | Ono Pharmaceutical Co | Tetrahydrocarboline derivative |
CN103201262B (zh) * | 2010-08-20 | 2016-06-01 | 艾米拉医药股份有限公司 | 自分泌运动因子抑制剂及其用途 |
WO2012127885A1 (ja) | 2011-03-18 | 2012-09-27 | 小野薬品工業株式会社 | テトラヒドロカルボリン誘導体 |
CN106220572B (zh) | 2011-10-28 | 2019-12-13 | 因西必泰克新有限公司 | 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法 |
EP2922821B1 (en) * | 2012-11-20 | 2019-07-31 | Biogen MA Inc. | S1p and/or atx modulating agents |
MY170260A (en) * | 2013-03-14 | 2019-07-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
CN105339370B (zh) | 2013-06-19 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎症性疾病的化合物和及其药物组合物 |
JPWO2015163435A1 (ja) * | 2014-04-24 | 2017-04-20 | 田辺三菱製薬株式会社 | 新規2−アミノ−ピリジン及び2−アミノ−ピリミジン誘導体及びその医薬用途 |
JP2016164154A (ja) * | 2015-02-26 | 2016-09-08 | 塩野義製薬株式会社 | オートタキシン阻害活性を有する7位無置換縮合ピラゾール誘導体 |
JP6703778B2 (ja) * | 2015-08-26 | 2020-06-03 | 塩野義製薬株式会社 | オートタキシン阻害活性を有する5位カルボニルアミノアルキル置換縮合ピラゾール誘導体 |
JP2017078039A (ja) * | 2015-10-20 | 2017-04-27 | 田辺三菱製薬株式会社 | 新規2−アミノ−ピリジン又は2−アミノ−ピリミジン誘導体を有効成分として含有する医薬組成物 |
JP2018141254A (ja) | 2017-02-28 | 2018-09-13 | 倉敷紡績株式会社 | ジャケット |
-
2019
- 2019-07-26 CN CN201980049820.0A patent/CN112469699B/zh active Active
- 2019-07-26 EP EP23164432.9A patent/EP4219452A1/en active Pending
- 2019-07-26 PL PL19841934.3T patent/PL3831812T3/pl unknown
- 2019-07-26 CA CA3103648A patent/CA3103648A1/en active Pending
- 2019-07-26 FI FIEP19841934.3T patent/FI3831812T3/fi active
- 2019-07-26 EP EP19841934.3A patent/EP3831812B1/en active Active
- 2019-07-26 AR ARP190102112A patent/AR115852A1/es unknown
- 2019-07-26 SG SG11202012524YA patent/SG11202012524YA/en unknown
- 2019-07-26 IL IL279702A patent/IL279702B2/en unknown
- 2019-07-26 US US17/258,682 patent/US11958812B2/en active Active
- 2019-07-26 AU AU2019311595A patent/AU2019311595B2/en active Active
- 2019-07-26 WO PCT/JP2019/029366 patent/WO2020022470A1/ja unknown
- 2019-07-26 KR KR1020217004752A patent/KR20210038896A/ko unknown
- 2019-07-26 DK DK19841934.3T patent/DK3831812T3/da active
- 2019-07-26 PT PT198419343T patent/PT3831812T/pt unknown
- 2019-07-26 MX MX2021001034A patent/MX2021001034A/es unknown
- 2019-07-26 BR BR112020027051-2A patent/BR112020027051A2/pt unknown
- 2019-07-26 TW TW108126565A patent/TWI833781B/zh active
- 2019-07-26 ES ES19841934T patent/ES2952939T3/es active Active
- 2019-07-26 HU HUE19841934A patent/HUE062356T2/hu unknown
- 2019-07-26 JP JP2020532490A patent/JP7440413B2/ja active Active
-
2021
- 2021-01-06 PH PH12021550061A patent/PH12021550061A1/en unknown
- 2021-01-18 ZA ZA2021/00352A patent/ZA202100352B/en unknown
-
2024
- 2024-02-15 JP JP2024021488A patent/JP2024056906A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7440413B2 (ja) | 2024-02-28 |
AU2019311595A1 (en) | 2021-01-07 |
EP4219452A1 (en) | 2023-08-02 |
IL279702B2 (en) | 2024-05-01 |
AU2019311595B2 (en) | 2024-01-04 |
TWI833781B (zh) | 2024-03-01 |
JPWO2020022470A1 (ja) | 2021-08-02 |
CN112469699A (zh) | 2021-03-09 |
BR112020027051A2 (pt) | 2021-03-30 |
PL3831812T3 (pl) | 2023-09-11 |
IL279702A (en) | 2021-03-01 |
AR115852A1 (es) | 2021-03-03 |
PH12021550061A1 (en) | 2021-12-06 |
EP3831812B1 (en) | 2023-05-10 |
US11958812B2 (en) | 2024-04-16 |
EP3831812A4 (en) | 2022-05-04 |
CN112469699B (zh) | 2024-02-23 |
KR20210038896A (ko) | 2021-04-08 |
ES2952939T3 (es) | 2023-11-07 |
DK3831812T3 (da) | 2023-06-26 |
MX2021001034A (es) | 2021-04-19 |
IL279702B1 (en) | 2024-01-01 |
WO2020022470A1 (ja) | 2020-01-30 |
EP3831812A1 (en) | 2021-06-09 |
HUE062356T2 (hu) | 2023-10-28 |
FI3831812T3 (fi) | 2023-07-04 |
ZA202100352B (en) | 2024-05-30 |
TW202019882A (zh) | 2020-06-01 |
PT3831812T (pt) | 2023-07-10 |
US20220298118A1 (en) | 2022-09-22 |
JP2024056906A (ja) | 2024-04-23 |
CA3103648A1 (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202012524YA (en) | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | |
ZA202102728B (en) | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof | |
SG11202011447UA (en) | Pyridone derivative, composition and use as antiviral drug thereof | |
EP3604306A4 (en) | MACROCYCLIC DERIVATIVE OF PYRAZOLE [3,4-D] PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
EP3402787A4 (en) | PROCESSES FOR PREPARING 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF | |
EP3479841A4 (en) | GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION COMPRISING SAME, AND THERAPEUTIC USE THEREOF | |
IL276952A (en) | History of 4,2-diaminoquinazolines and their medicinal uses | |
EP3481831A4 (en) | NOVEL 4-AMINOPYRAZOLO [3,4-D] PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
IL251780B (en) | Derivatives of 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-h1-pyrrolo[c-3,2] pyridine and pharmaceutical preparations containing them | |
IL283533A (en) | Pentatein derivatives and their uses | |
EP3572409A4 (en) | 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
SG11202011685QA (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
EP3802495A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE | |
IL285025A (en) | History of heterocyclic carboxamides, their preparation and use | |
EP3805234A4 (en) | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE | |
EP3807282A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE | |
EP3845527A4 (en) | MULTISUBSTITUTED PYRIDONE DERIVATIVES AND THEIR MEDICAL USE | |
EP3490978A4 (en) | SALTS OF 2, 6-DIMETHYLPYRIMIDONE DERIVATIVES AND THEIR USES | |
GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
EP3715344A4 (en) | 1,4-BENZODIAZAPINE-2-ON DERIVATIVES AND THEIR USES | |
IL282142A (en) | The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine | |
IL278009B1 (en) | History of 6,2-diamino-4,3-dihydropyrimidin-4-one and its use in treatment | |
SI3778609T1 (sl) | Derivati penama ali njenih soli, farmacevtski sestavki in njihova uporaba | |
EP3579825A4 (en) | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND USES THEREOF AS MEDICINES FOR TREATMENT OF LIVER FIBROSIS | |
EP3983415A4 (en) | HETEROCYCLIC DERIVATIVES AND USE THEREOF |